title: Etanercept treatment in juvenile idiopathic arthritis: the Polish registry.
abstract: BACKGROUND
  To evaluate the long-term safety and efficacy of etanercept treatment in Polish patients with juvenile idiopathic arthritis (JIA).
  
  
  METHODS
  The study involved patients, fulfilling the JIA criteria of the International League of Associations of Rheumatology (ILAR), who were started on etanercept therapy after methotrexate and other synthetic disease-modifying antirheumatic drugs (DMARDs) had proven ineffective. Patient data were collected in an electronic registry. Disease improvement was assessed based on Giannini's criteria.
  
  
  RESULTS
  The statistical analysis involved 188 patients. Significant improvement was observed in all clinical and laboratory parameters after the first month of therapy and was maintained in the following months. ACR Pediatric 30, 50, 70, 90, and 100 improvement was observed in 81.4%, 65.9%, 27.5%, 16.2%, and 15%, respectively, of patients after 3 months and in 94.7%, 88.4%, 62.1%, 34.7%, and 26.3%, respectively, after 24 months of treatment. Throughout the 72-month safety observation period, 1162 adverse events were reported; the exposure-adjusted AE rate was 2.96 per patient per year.
  
  
  CONCLUSIONS
  In patients with various subtypes of JIA resistant to conventional DMARD treatment, etanercept resulted in significant and long-lasting improvements in disease activity. Combination treatment with etanercept and a DMARD was well tolerated.
authors: St Louis Children's Hospital, Cracow, Poland.
authors: Zbigniew
authors: Z
authors: Zuber
authors: Lidia
authors: L
authors: Rutkowska-Sak
authors: Jacek
authors: J
authors: Postępski
authors: Bogna
authors: B
authors: Dobrzyniecka
authors: Violetta
authors: V
authors: Opoka-Winiarska
authors: Katarzyna
authors: K
authors: Kobusińska
authors: Piotr
authors: P
authors: Gietka
authors: Violetta
authors: V
authors: Osińska
authors: Dorota
authors: D
authors: Turowska-Heydel
authors: Izabela
authors: I
authors: Szczygielska
authors: Beata
authors: B
authors: Kołodziejczyk
authors: Anna
authors: A
authors: Świątek-Baczkowska
authors: Agnieszka
authors: A
authors: Gazda
authors: Piotr
authors: P
authors: Wiland
authors: Witold
authors: W
authors: Tłustochowicz
authors: Ewa
authors: E
authors: Tuszkiewicz-Misztal
mesh_terms: D000293:Adolescent; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D003710:Demography; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D011044:Poland / Q000453:epidemiology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012042:Registries; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept